https://phys.org/news/2018-11-fungal-production-platform-c1-vaccines.html

VTT and Dyadic will present data regarding the development of an extremely low protease and high-producing platform strain that has resulted in the production of stable therapeutic antibodies with a final production rate of over 2.6 grams/litre/day. Furthermore, several difficult-to-express proteins, such as vaccine antigens and bispecific antibodies, have been produced at good levels in C1 as well as a specific primary metabolite through the metabolic engineering of C1. Additionally, specific information will be presented on the glycoengineering work to humanize the glycosylation machinery of C1 that has also generated promising results.

In addition, from the start of 2017 until now, Dyadic and VTT have established research projects with 10 groups including top pharmaceutical companies such as Mitsubishi Tanabe Pharma and Sanofi-Aventis. So far, research milestones have been successfully achieved in all the completed projects.